Pulse Biosciences, Inc
PLSE Healthcare Medical Instruments & Supplies
Pulse Biosciences, Inc’s revenue for fiscal 2025 (year ended December 2025) was $350,000.00, down 50.0% from fiscal 2022.
- Revenue
- +359.3%
- EPS
- −10.3%
- Free cash flow
- −1,180.5%
Quarter to September 2026, against a year earlier
Follow PLSE
Alert me
Pulse Biosciences, Inc (PLSE) EV/FCF
As of 5 November 2026, Pulse Biosciences, Inc (PLSE) trades at a EV/FCF of −17.8×. Over the past ten years it has ranged from −61.6× (September 2026) to −0.6× (August 2022); the current reading is higher than 32% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | −16.7× | — |
| FY2022 | −2.1× | — |
| FY2021 | −7.3× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | −16.8× | — |
| Jun 2026 | −30.7× | — |
| Mar 2026 | −26.4× | — |
| Dec 2025 | −16.7× | — |
| 6 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| STVN Stevanato Group S.p.A. compare | −453× |
| PLSE Pulse Biosciences, Inc | −17.8× |
| MMED MiniMed Group, Inc. compare | −10.9× |
| NVST Envista Holdings Corporation compare | 18.0× |
| MMSI Merit Medical Systems, Inc. compare | 24.7× |
| ICUI ICU Medical, Inc. compare | 25.5× |
| ATRC AtriCure, Inc. compare | 125× |
| WRBY Warby Parker Inc. compare | 139× |
| TFX Teleflex Incorporated compare | 172× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on PLSE
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Altman Z-score
- The full statement